DCIR3 Inhibitors
DCIR3 (Dendritic Cell Immunoreceptor 3), a member of the C-type lectin family, plays a crucial role in immune regulation by modulating dendritic cell function and antigen presentation. The chemical class known as DCIR3 Inhibitors comprises compounds targeting specific signaling pathways implicated in DCIR3-mediated immune responses. Central to this class are inhibitors of Janus kinases (JAKs), such as Ruxolitinib, CP 690550, Baricitinib, and TG101348. These compounds directly interfere with JAK-STAT signaling, a pathway intricately linked to DCIR3 function in immune regulation. By inhibiting JAKs, these compounds potentially modulate DCIR3-mediated immune responses.
Sotrastaurin, TAK-632, AZD8330, and Cobimetinib target protein kinase C (PKC) and MEK in the MAPK pathway, indirectly affecting DCIR3 function. By modulating these key signaling nodes, these compounds have the potential to impact DCIR3-mediated immune responses. Axitinib, Sorafenib, and Everolimus target VEGFR, RAF, and mTOR, respectively, providing indirect means to influence DCIR3 activity. These compounds, by modulating angiogenic and mTOR-related pathways, may impact DCIR3 function in immune regulation. In summary, the DCIR3 Inhibitors class comprises compounds targeting critical signaling pathways involved in dendritic cell function and immune responses. Understanding the intricate interplay between these inhibitors and DCIR3 sheds light on strategies for modulating immune regulation and holds promise for discoveries in immune-related disorders.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib inhibits JAK1 and JAK2, influencing the JAK-STAT pathway. Its direct impact on DCIR3 involves suppression of JAK-mediated signaling, potentially affecting DCIR3 function in immune regulation. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Baricitinib inhibits JAK1 and JAK2, affecting the JAK-STAT pathway. Its direct modulation of DCIR3 involves suppression of JAK-mediated signaling events, potentially influencing DCIR3 function in immune regulation. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
TG101348 inhibits JAK2 and FLT3, impacting the JAK-STAT pathway. Its direct impact on DCIR3 involves interference with JAK2-mediated signaling, potentially affecting DCIR3 function in immune regulation. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin inhibits PKC, affecting multiple signaling pathways. Its direct impact on DCIR3 involves suppression of PKC-mediated signaling events, potentially influencing DCIR3 function in immune regulation. | ||||||
TAK 632 | 1228591-30-7 | sc-473801 | 5 mg | $224.00 | ||
TAK-632 inhibits MEK, affecting the MAPK pathway. Its indirect influence on DCIR3 involves modulating the MAPK pathway, potentially impacting DCIR3-mediated immune responses. | ||||||
AZD8330 | 869357-68-6 | sc-364425 sc-364425A | 5 mg 10 mg | $255.00 $450.00 | ||
AZD8330 inhibits MEK, affecting the MAPK pathway. Its indirect impact on DCIR3 involves modulation of the MAPK pathway, potentially influencing DCIR3 function in immune regulation. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib inhibits MEK1 and MEK2, affecting the MAPK pathway. Its indirect modulation of DCIR3 involves suppression of the MAPK pathway, potentially influencing DCIR3-mediated immune responses. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including RAF. Its indirect impact on DCIR3 involves modulation of RAF-related pathways, potentially influencing DCIR3-mediated immune responses. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits mTOR, affecting the mTOR pathway. Its indirect influence on DCIR3 involves suppression of mTOR-related pathways, potentially impacting DCIR3 function in immune regulation. | ||||||